Alvotech Warrant closed at $0.38 on Sep 28, up 2.68%, 80.5% below its highest close since Jun 16. Volume of 2.1K shares was 1.35× its 20-day average (above normal).
Split-adjusted performance: +0.0% over one month, +22.5% over six months.
Short interest was 729 shares at the Sep 15 settlement (2.4 days to cover).
No reported quarters with price history yet.
Not enough peers to rank
Alvotech is a biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients globally. Its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases. The company's commercialized products incldue AVT02, AVT03, AVT04, AVT05, and AVT06. Its pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, and cancer. Geographically, the company generates the majority of revenue from Europe, and the rest from the USA and the rest of the world.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
